Literature DB >> 3033213

Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.

D M Zimmerman, J D Leander, J K Reel, M D Hynes.   

Abstract

Systemic administration of beta-funaltrexamine (beta-FNA) 24 hr before analgesic testing produced approximately a 10-fold parallel shift in the dose-response curves of the prototypic mu agonists morphine, I-methadone, fentanyl and etorphine in the mouse abdominal constriction test. In contrast, prior administration of beta-FNA produced no appreciable shift in the analgesic dose-response curve of the selective kappa agonist, U-50, 488H. These results suggest that beta-FNA is selective for mu over kappa receptors under the conditions used in this study. The dose-response curves for ethylketazocine and proxorphan were affected only to a small extent by beta-FNA pretreatment, suggesting that these compounds have analgesic actions mediated primarily through nonmu, probably kappa receptors. The dose-response curves for cyclazocine, buprenorphine, butorphanol, nalorphine and nalbuphine were shifted markedly to the right and frequently not in a parallel fashion by the prior administration of beta-FNA. These results seem to indicate a major role for the mu receptor in the analgesic actions of these compounds.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033213

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

1.  Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor.

Authors:  Mark A Smith; Keith A Gordon; Christopher K Craig; Paul A Bryant; M Eric Ferguson; Adam M French; Jason D Gray; Jacob M McClean; Jonathan C Tetirick
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

2.  Mu-opioid component of the ethylketocyclazocine (EKC) discriminative stimulus in the rat.

Authors:  K W Locke; B Gorney; M Cornfeldt; S Fielding
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

Review 4.  The switch from buprenorphine to tapentadol: is it worth?

Authors:  Adriana Miclescu
Journal:  Rom J Anaesth Intensive Care       Date:  2016-10

5.  Social and environmental influences on opioid sensitivity in rats: importance of an opioid's relative efficacy at the mu-receptor.

Authors:  Mark A Smith; Kara A Chisholm; Paul A Bryant; Jennifer L Greene; Jacob M McClean; William W Stoops; David L Yancey
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

6.  Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay.

Authors:  J H Broadbear; S S Negus; E R Butelman; B R de Costa; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

7.  Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.

Authors:  C Gouardères; K Jhamandas; M Sutak; J M Zajac
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

8.  Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.

Authors:  Priyank Kumar; Soujanya Sunkaraneni; Sunil Sirohi; Shveta V Dighe; Ellen A Walker; Byron C Yoburn
Journal:  Eur J Pharmacol       Date:  2008-08-30       Impact factor: 4.432

9.  Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior.

Authors:  András Váradi; Gina F Marrone; Shainnel O Eans; Michelle L Ganno; Joan J Subrath; Valerie Le Rouzic; Amanda Hunkele; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2015-09-14       Impact factor: 4.418

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.